Biovica International Biovica, active in blood-based cancer monitoring, has signed a master service agreement with a biopharmaceutical company enabling Biovica to provide its TKa testing assay and testing services.
Dassault Systèmes announced it collaborated with CDR-Life, a Swiss biotherapeutics company, to accelerate CDR-Life’s development of next-generation highly tumor-selective immunotherapies using CDR-Life’s proprietary M-gager® platform.
Roche introduces navify Analytics, its suite of cloud-based solutions that provide actionable insights to optimise operational and financial outcomes in laboratories and point of care settings.
GenSight Biologics announced initial results of new meta-analyses in Leber Hereditary Optic Neuropathy, which show those treated with LUMEVOQ® gene therapy experienced a rate of visual recovery greater than that of idebenone-treated patients and untreated patients.
Sirnaomics Ltd. will present its preclinical and clinical development of its GalAhead™ technology-based programs, focusing on an innovative dual-targeted-GalNAc design, muRNA platform drug candidates, at the upcoming 2024 OPT Congress, which took place in Boston, USA from March 13-14, 2024.
MaaT Pharma will present extended results from its Early Access Program for patients with aGvHD that were treated with MaaT013 and, for the first time, Overall Survival data after 12 months in more patients.
Casio Computer Co., Ltd. announced that the DZ-C100 COLPOCAMERA, which is designed for uterocervical observation and photography in gynecological settings, and the CST-100M camera stand are released in the US, Australia and New Zealand.
Cognition Therapeutics, Inc. announced that it has priced an underwritten public offering of 6,571,428 shares of its common stock at an offering price of $1.75 per share of common stock.
Belite Bio, Inc announced its audited financial results for full-year 2023 and the unaudited and unreviewed financial results for the quarter ended December 31, 2023, and provided a business update.
Everest Medicines’s licensing partner Calliditas Therapeutics AB announced that the U.S. FDA has granted an orphan drug exclusivity period of seven years for Nefecon®, expiring in December 2030 based on Calliditas obtaining full approval with a new indication for this drug product in December 2023.
